The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Updates on targeting PI3 kinase gamma in myeloid malignancies
Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents updates on targeting PI3 kinase gamma in myeloid malignancies. Dr Lane discusses the potential of PI3 gamma inhibition as a single agent in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as in combination with chemotherapy, hypomethylating agents, or venetoclax. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
